A phase I/II randomized trial in 2019 in patients with relapsed refractory multiple myeloma is designed to evaluate two agents, anti-LAG-3 and anti-TIGIT, for their immune effects and safety as single agents and in combination with pomalidomide and dexamethasone. Here, TIGIT is linked to plasma cell myeloma.